Logo

Alercell Lena Q51 Leukemia Diagnostic Test (RUO)

Jan 27, 2023

Alercell, a Bozeman, Montana-based molecular diagnostics company, has launched the Lena Q51 leukemia diagnostics test for research use only. The assay is designed to detect up to 51 gene mutations associated with leukemia in order to improve patient outcomes and help physicians select appropriate therapeutics for leukemia patients. Test results are available in under three hours using a standard qPCR machine and standard PCR and DNA purification technology, the company said. Alercell is also currently completing clinical trials and regulatory submissions to support US Food and Drug Administration approval.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.